{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000700","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.254884+00:00","generated_at":"2026-06-15T03:40:52.723944+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunic Q1 net loss $25.3M; positive phase 1b IMU-856 celiac data; cash $97.1M","bullets":["Q1 net loss $25.3M ($0.58/sh) vs $20.8M ($0.74/sh); R&D expenses $23.0M up from $17.4M YoY.","Cash, equivalents and investments $97.1M as of Mar 31, 2023; expected to fund operations into Q4 2024.","Positive phase 1b IMU-856 celiac data: proof-of-concept with improvements in histology, symptoms, biomarkers, nutrient absorption.","Interim results from phase 2 CALLIPER trial of vidofludimus calcium in progressive MS expected H2 2023.","Richard Rudick, M.D. added to board Apr 26, 2023; Vincent Ossipow, Ph.D. to step down June 28, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000700","json":"https://secwatch.observer/filing/0001193805-23-000700.json","markdown":"https://secwatch.observer/filing/0001193805-23-000700.md","text":"https://secwatch.observer/filing/0001193805-23-000700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000700/0001193805-23-000700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000700/e618615_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:40:52.723944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73d5c68b41e720d2e19f81d413554a0d4c990ed1","claim":"IMMUNIC, INC. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and providing a corporate update (the “Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000700/0001193805-23-000700-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}